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Background: In recent years, personalized medicine (PM) has become a highly regarded line of development in
medicine. Yet, it is still a relatively new field. As a consequence, the discussion of its future developments, in
particular of its ethical implications, in most cases can only be anticipative. Such anticipative discussions, however,
pose several challenges. Nevertheless, they play a crucial role for shaping PM’s further developments. Therefore, it is vital
to understand how the ethical discourse on PM is conducted, i.e. on what – empirical and normative – assumptions
ethical arguments are based regarding PM’s current and future developments.
Methods: To gather this information, we conducted a qualitative interview study with stakeholders in the German
health care system. Our purposive sample included 17 representatives of basic research, clinical research, health
economics, regulatory authorities, reimbursement institutions, pharmaceutical industry, patient organizations, as well as
clinicians and legal experts involved in PM developments or policy making. We used an interview guide with open-ended
questions and analyzed transcriptions of the interviews by means of qualitative content analysis.
Results: The respondents addressed a multitude of concerns in the context of research on as well as application of
personalized preventive and therapeutic measures both on the individual and on the societal level. Interestingly,
regarding future developments of PM the ethical evaluation seemed to follow the rule: the less likely its application,
the more problematic a PM measure is assessed. The more likely its application, on the other hand, the less
problematic it is evaluated.
Conclusions: The results of our study suggest re-focusing the ethical discourse on PM in Germany towards a
constructive ethical monitoring which ensures to include only, nevertheless all of the actual and/or potential concerns
that are ethically relevant in order to allow balancing them against the actual and potential ethically relevant benefits of
PM measures. To render this possible, we propose a strategy for evaluating ethical concerns in the context of PM.Background
In recent years, so-called personalized medicine (PM) has
become a highly regarded line of development in modern
medicine. Basically, this trend results from the overarching
goal of PM to develop tailored approaches of prevention
and treatment for certain patient subpopulations. The basic
concept thereby consists of identifying genetic, phenotypic,
or environmental factors, which affect the subpopulation’s
health risks and help to find the most appropriate type
and dose of medication and/or intervention. In detail, PM* Correspondence: sebastian.schleidgen@med.lmu.de
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distribution, and reproduction in any mediumpromises the following benefits: [1-4] first, it is expected to
permit an early identification of persons who carry a
genetic or phenotypic variation that increases their risk
for developing a certain disease. This would allow preventive
measures before disease outbreak. Second, possibilities of
better diagnostic and prognostic assessment of diseases
are expected resulting in earlier and improved therapeutic
interventions. Third, PM is anticipated to develop more
effective and safer treatment strategies based on increased
knowledge about individual determinants of diseases.
Finally, an identification of patient subgroups, which will
benefit from a certain therapy, is awaited. This could
result in reduced trial and error prescribing with improved
effectiveness and efficiency of care.BioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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concerns: [1-3,5-10] first, with regard to research on PM,
measures of adequately implementing informed consent
for biomarker studies is discussed as well as issues of
confidentiality, data protection and the individuals’ right
to know/not to know. Furthermore, it is debated how to
allocate resources into as well as within different fields of
research on PM in ethically justified ways. Second,
when looking at the clinical usage of PM measures,
concerns are expressed that predictive test results
may influence individual well-being negatively, increase
individual responsibility for one’s health or lead to (genetic)
discrimination of persons with predispositions for certain
diseases. As regards personalized diagnostic test results,
worries are articulated that individuals with a certain
response rate to a drug could be (genetically) discriminated.
Moreover, in reference to personalized therapeutic
measures, it is suspected that establishing small patient
subgroups may lead to insufficient drug testing before their
application and thus result in higher risks for patients. Both
with regard to personalized prevention and personalized
treatment, issues of confidentiality and data protection as
well as the individual’s right to know/not to know are
discussed. Finally, it is argued that PM measures may lead
to significant cost increases and thus result in an
additional financial burden for the health care systems.
This, it is suspected, could further exacerbate problems of
equal access to health care services.
However, PM, understood as biomarker-based targeted
treatment or prevention, is still a relatively new field:
in Germany, for instance, only 27 drugs are currently
authorized for personalized treatment, i.e. their application
is based on preceding diagnostic tests on efficacy or
(potential) side effects [11]. Meaningful numbers for
predictive tests or preventive measures do not exist.
Therefore, analysis of PM’s future development, in particular
of its opportunities and risks as well as its ethical
implications, in most cases can only be anticipatory. Such
anticipative discussions, however, pose several challenges,
primarily the risks of debating irrelevant ethical concerns
or – more importantly – neglecting relevant ones, if
debates are not based on a realistic assessment of current
and future developments. Nevertheless, such debates play
a crucial role for shaping PM’s further developments.
Therefore, it is vital to understand how the ethical
discourse on PM is conducted, i.e. on what – empirical
and normative – assumptions ethical arguments are
based regarding PM’s current and future developments.
Additionally, it is highly relevant for an adequate ethical
monitoring of PM which ethical implications are considered
relevant – and which are neglected. Researchers and
clinicians who are involved in the development of PM
can provide valuable insights both into the current state
of development of PM and into the ethical discourse onPM. Furthermore, an examination of ethical concerns
requires input from stakeholders of the health care system
in which a PM measure is developed and/or used. To
gather this important information, we conducted a
qualitative interview study with stakeholders in the
German health care system.
In detail, the study aimed at answering the following
questions: What is the current state of developments of
PM? What prospects does PM offer according to the
stakeholders’ opinions, i.e. what are the medical areas in
which they expect the most significant progress?
Which areas are considered less important? What ethical
implications of PM are expected, in general and more
specifically for the German health care system? The
results of this study provide a clearer picture of the
perspectives of the rapidly growing field of PM. Moreover,
they suggest re-focusing the ethical discourse on PM in
Germany, especially regarding a realistic assessment of
PM’s current state of development and clinical usage as
well as expected future developments.
Methods
Sample
To collect as many different stakeholder perspectives as
possible, we selected participants in accordance to the
criterion of maximum variation regarding their professional
role in the German health care system. The purposive
sample [12] included representatives of basic research,
clinical research, health economics (including statisticians),
regulatory authorities, reimbursement institutions, pharma-
ceutical industry, patient organizations, as well as clinicians
and legal experts involved in PM developments or policy
making. Leading representatives of each stakeholder group
were selected and contacted by mail. The letters included
an outline of the project objectives as well as a request for
cooperation and informed consent. Ethics approval was
not necessary as our study only included experts in the
field of PM and did neither endanger the respondents’
psychological or physical health (MBO-Ä §15.1) nor contain
any drug or medical device research (AMG §40.1,
MPG §20.1). Participants were recruited until a point of
saturation was reached, i.e. when the additional interviews
provided no further information. Saturation was reached
after interviewing 17 participants (Table 1).
Data collection and analysis
We conducted semi-structured interviews based on
an interview guide with open-ended questions on
the stakeholders’ assessments of current trends and
developments as well as their expectations and concerns
regarding PM. Except for two interviews, which took place
at the interviewers’ office, all conversations were carried
out at the respective participants’ office. The interviews
took about one hour each. All conversations were held
Table 1 Participants: professional roles
Occupation Number Ratio
Basic Research (BR) 2 12%
Clinical Research (CR) 1 6%
Health Economics (HE) 3 18%
Regulatory Authorities (RA) 1 6%
Reimbursement Institutions (RI) 1 6%
Pharmaceutical Industry (PI) 4 24%
Patient Organizations (PO) 1 6%
Clinicians (C) 2 12%
Legal Experts (LE) 2 12%
Sum 17 100%*
* Difference in Sum due to Rounding.
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consistently by the same interviewer (SS; trained in
qualitative methods). They were audio recorded; the
interview guide was adapted to the current state of findings
at several stages of the study.
In order to render this adaptation possible as well as
to determine the point of saturation, data collection
and data analysis were carried out simultaneously. The
interviews were transcribed and analyzed following the
qualitative content analysis according to Mayring [13]
with the software MAXqda. For this purpose, the interview
passages relevant to our research questions were identified
and coded in order to develop generalizations of the
individual statements and conclude overarching categories
(Additional file 1). Codes and categories were validated
internally (by intercoder consensus) as well as externally
(by discussion with experts in the field of qualitative
research). As all interviews were conducted in German,
the interview passages quoted below are direct translations
of the originals. To ensure the least possible bias the
passages were translated by an English native speaker.
Results
The results are divided into three sections: first, the
stakeholders’ assessments of the current state of research
as well as the clinical use of PM measures are presented.
The second section depicts the respondents’ expectations
regarding future developments of PM. Finally, their ethical
concerns are presented.
Current state of PM
Personalized therapeutic interventions
Overall, the stakeholders were rather skeptical with
regard to the current state of research and clinical use of
personalized therapeutic measures. One respondent even
questioned the scientific basis of PM and considered the
underlying idea as inadequately reductionist, i.e. slanted
toward molecular factors:(1)(RI) Momentarily, there is actually nothing that
speaks in favor of this being more than just
humoralism or something like that. It goes a little
further, in that it differs in its biotechnological
foundations […], but I initially doubt the whole
thing […] for the same reason that basically all other
assumptions, which have constituted the basis of a
theoretical body with this absoluteness in medicine,
turned out to be false.
According to this respondent, the current emphasis on
PM is primarily driven by the economic interests of the
pharmaceutical industry:
(2)(RI) This is primarily a propagandistic idea by the
pharmaceutical industry, which recognized that one
could achieve increasingly higher prices for niche
products.
Other participants were less critical, but still rather
skeptical: Although several personalized therapeutic mea-
sures are already applied, their added therapeutic bene-
fit was considered rather small compared to standard
interventions:
(3)(C) The [classical chemotherapy] is not that much
worse in many cases. There is not a large discrepancy
and many patients often are too optimistic on what
antibodies and modern cancer therapies can achieve.
The two only differ by a few months [of survival].
One respondent additionally considered insufficient
possibilities of data management as a major problem.
Surprisingly, another respondent suggested that economic
interests could be a major reason why PM is not further
advanced in its development:
(4)(PO) We also noticed that, conspicuously, the
pharmaceutical industry, and this is just a feeling, I do
not have any evidence that this is true, is slowing the
whole process down. […] One could assume that the
pharmaceutical industry thinks along the lines of:
well, if we support research efforts then we are risking
that the sales volume for substance X will not remain
as large because it will be implemented selectively.
Personalized preventive interventions
Regarding the current state of personalized prevention,
the stakeholders were even more skeptical: on the one
hand, predictive tests for some conditions, such as
Alzheimer’s disease, already exist, tests for other conditions
are in development. On the other hand, there are currently
hardly any corresponding interventions that could
effectively prevent disease outbreak:
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when combining all of the available parameters
allows one to determine to 95 percent who will
suffer from Alzheimer’s at a later point. However, to
this day, we do not have the possibility of fighting it
in any way. So, we do know a lot about this disease
[…], but even with all of our molecular
understanding, we have no chance of interfering
properly or halting this process in any way.
Future perspectives of PM
Personalized therapeutic interventions
The assessment of future perspectives of PM showed a
similar picture as in the case of assessing the current
state of research and clinical use: one stakeholder critically
noted that the current focus on PM merely results from
an exaggeration and it, thus, will not experience any
significant future developments:
(6)(RI) I believe that the whole discussion concerning
personalized medicine is experiencing a phase of
disillusionment, which is part of the typical cycle
that such hypes undergo. I also indeed believe that if
it is possible to successfully establish an objective,
rational point of view of the actual possibilities, then
this disillusionment will increase.
According to this respondent, the lack of good prospects
results from the scientifically inadequate reductionist
approach of PM. Another stakeholder predicted that the
extremely high costs of PM will ultimately render a break-
through impossible. Most respondents, however, held the
opinion that treatment approaches based on stratification,
i.e. identifying patient subgroups based on biomarkers,
in the medium and long term would experience a
breakthrough:
(7)(RA) This medicine, I would say, has a future, a very
significant future, however, not within the next two
years. In fact, if I take the scientists that are working
on this seriously, then this is a process that,
according to them, will take about another ten years
until one can truly say that this is a secure application
of medical findings that are evidence-based and
confirmed through research.
(8)(PI2) [W]e will move forward step by step. I believe that
we will have more and more therapeutic stratification
based on the molecular structure of the body.
According to some respondents, the potential of PM
consists primarily in improving the choice of drugs as
well as their dosage based on diagnostic tests. Moreover,
personalized therapeutic measures may provide higher
efficacy and efficiency, which, in turn, could result inadditional benefits for the patients as well as a positive
cost impact on the health care system. However, in order
to render such developments possible, more basic,
translational, and applied research would be necessary.
Due to the vast amount of data gained in the course of
such research, good information and data management
would be of particular importance:
(9)(BR) The least we can say is that this process will be
a long and enduring one. Nevertheless, I still
consider it to be possible and achievable. It has a lot
to do with the fact, I think, that we can accumulate
and merge knowledge better and thus, bring about
new findings […]. I think […] momentarily, we are
limited by the fact that each individual scientist who
works in their respective field does not possess all of
the information needed to create an overall concept.
Personalized preventive interventions
Compared to personalized treatment, the future perspec-
tives of personalized prevention were assessed much more
skeptical in almost every interview: several respondents
doubted that an adequate medical and scientific foundation
of personalized prevention is possible at all. The underlying
idea of personalized prevention, however, was predom-
inantly conceived as a vision worth seeking:
(10)(PI1) However, it would be ideal if we could finally
move in the direction of prevention by using
biomarkers through certain diagnoses. Not just
offering treatment for a disease, but rather avoiding
the disease. This would be a vision that one should
pursue.
Ethical implications of PM
Personalized therapeutic interventions
With respect to personalized therapeutic measures, the
prevailing ethical concerns were issues of distributive
justice due to escalating costs of care which could result
in unequal access to PM interventions:
(11)(BR) I just heard that if a breast cancer patient is
between the age of 35 and 45 then she will, more or
less, have no problems receiving a prescription for
[Herceptin]. If she is between the age of 55 and 65,
then she will have a major problem getting the
prescription and, if she is insured with the AOK
[major public health insurance provider in Germany],
she will most likely not get the prescription at all. So,
it is thus calculated what the life of a 65-year old is
worth. Is it worth it to possibly have to spend 50,000
Euros annually for the treatment of this patient? […]
What does personalized medicine mean for the equal
treatment of patients?
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that personalized therapies based on stratification may
contribute to the solution of existing distributional issues
by reducing inefficiencies. Finally, several respondents
expressed the fear that stratification may result in
additional risks for patients: as clinical studies on
personalized therapeutic measures can be carried out with
small patient groups only, drugs might be authorized
without being sufficiently tested, especially with respect to
possible side effects.
Personalized preventive interventions
With reference to personalized prevention, most of the
respondents mentioned problems of confidentiality, the
handling of sensitive genetic data, as well as the possibility
of ethnic discrimination or inequalities regarding health
insurance and chances on the job market. Furthermore,
many stakeholders expressed their worries about a growing
attribution of individual responsibility for one’s own health
as a consequence of improved means of prevention. Of
central concern, however, were potential consequences of
prognostic test results on individual well-being:
(12)(HE) A label is established and this label does
something to human beings. Basically, the passing
on of information is a type of intervention. In the
worst case, this leads to fear and low-spirits,
depression, and so on.
According to some respondents, this problem is apparent
especially in view of possible false-positive prognostic test
results.
Research on PM
With regard to research, primarily aspects of resource
allocation were discussed, in particular allocation of
resources into the development of personalized thera-
peutic approaches. One respondent urged to examine the
expected additional benefit in relation to the incurred
costs in order to prevent an excessive and unjustified
allocation of resources into the research of PM:
(13)(BR) One question that continuously consumes us
and that, I personally believe, has not been answered
satisfactorily, and where parameters have to be set
up, is: is it recommendable, from a health
economics perspective, to go this way? If we go
ahead with stratification and then […] we end up
having to wait for the final answer: did he survive or
not? Instead, I would prefer to have parameters
beforehand so that I can intervene.
Regarding research practice, the problems of informed
consent, privacy of personal data, as well as the right toknow/not to know were the focus. Additionally, many
interviews centered on the debate on appropriate study
designs in the context of approving new drugs, with a
common critique of the prevailing use of surrogate
parameters:
(14)(RI) We go so far as to say that progression-free
survival is not enough, instead, one needs to be able
to have a longer life in good quality.
(15)(RA) Especially with regard to cancer therapies,
there is hardly any research that is conducted along
the lines of these [patient-relevant] outcomes, but
instead they are conducted according to surrogate
parameters. […] However, this has nothing to do
with the patients’ quality of life.
On the other hand, one respondent expressed the
opinion that standards for clinical trials are too demanding.
As a consequence, clinical trials would require too
much time and effort before therapeutic measures can
be launched which, in turn, would lead to an unjustified
negative impact on patients that could have benefitted
from an earlier introduction. Therefore, standards for
clinical trials should be scaled down, even if this results
in higher risks for patients.
Discussion
To summarize, all statements concerning the state of
PM can be assigned to either of two categories: (I)
“development of PM is in its fledgling stages” (optimistic)
or (II) “the approach of PM is unsound” (pessimistic),
where there is a clear predominance on part of category
(I) (15 of 17 respondents). However, even the optimistic
respondents assessed the research state of therapeutic
measures much more positively than the state of measures
of primary prevention.
A similar picture was drawn regarding future perspectives
of PM: On the one hand, some stakeholders were generally
pessimistic regarding future developments. On the other
hand, however, optimistic assessments, which ascribe
great potential to personalized treatment approaches based
on stratification, clearly dominate. Nevertheless, most of
the optimistic stakeholders assessed future developments
of personalized prevention rather pessimistically. A third
group of stakeholders felt unable to predict future
developments: according to them, the plausibility of PM’s
basic idea as well as its additional benefits for patients
needs to be proven first in order to render informed
predictions possible. In their opinion, PM’s cost impact on
the health care system should also be clarified before
making forecasts regarding its development.
It has to be noticed, however, that at least some of the
assessments of PM’s current and future perspectives
seem to follow the respective stakeholder’s interests: one
Schleidgen and Marckmann BMC Medical Ethics 2013, 14:20 Page 6 of 8
http://www.biomedcentral.com/1472-6939/14/20representative of the reimbursement institutions, for
instance, assesses PM pessimistically as “a propagandistic
idea by the pharmaceutical industry” (interview passage (2)).
A representative of patient organizations, on the other
hand, grounds his pessimistic evaluation on the suspicion
that “the pharmaceutical industry […] is slowing the
whole process [of developing PM] down” due to
economic considerations (4). Representatives of the
pharmaceutical industry, in turn, assess PM, especially its
future perspectives, much more optimistic (8), even with
regard to personalized prevention (10). These exemplary
statements seem to represent the actual competitive
situation in the German healthcare system: whereas
pharmaceutical companies in recent years increasingly
changed their strategy towards development and marketing
of PM [14], patient organizations as well as reimbursement
institutions are taking a critical look at exactly these
changes.
In contrast to such competitively motivated assessments,
it is striking that almost all respondents agreed in exclu-
sively alluding to the field of oncology as regarding
future perspectives of therapeutic PM measures. Only one
expert additionally referred to personalized approaches of
pain management, another explicitly demanded research
in medical areas outside oncology. This is remarkable
as approaches of PM increasingly are discussed outside
oncology [3]. Besides, in Germany several interventions
outside oncology are already established, e.g. agents for
treating epilepsy, HIV/AIDS or multiple sclerosis [11].
In contrast to such developments, the respondents’
focus suggests that the most significant progress of PM
can probably be expected in oncology – and that the
development of PM in other medical field might be
neglected. A possible reason for this is the fact that PM is a
rather heterogeneous field of development and application.
As a consequence, the respondents’ focus on oncology
is probably due to the specific composition of our sample,
i.e. the respondents’ specific working fields and personal
interests.
When turning to the ethical implications of PM, the
participants addressed concerns in PM’s various fields
both on the individual and on the societal level as shown
in Table 2.
It is of interest that no concerns were mentioned that
exclusively arise in the field of PM, but rather issues that
are well-known from other contexts, such as biobanking,
(conventional) genetic diagnostics, and other fields of
biomedical research. Besides, the respondents did neither
mention (potential) distributional issues regarding
personalized preventive measures nor did they allude to
concerns of data protection, right to know/not to know or
potential (genetic) discrimination regarding personalized
therapeutic measures. Concerning the issues of data
protection as well as the right to know/not to know, it isintriguing that another German interview study found
that experts in the field of PM pointed exactly to these
issues [10]. It is, however, important to realize that the
study’s sample (n=19) consisted exclusively of researchers
and clinicians involved in the same research group working
on PM in the field of colorectal cancer. In contrast, the
ratio of researchers (including basic researchers) and
clinicians was 5 out of 17 in our sample. This difference
in sample composition might explain the different focus
of the involved experts regarding ethical concerns in the
field of PM. It has to be noticed, however, that the results
of the two studies generally are difficult to compare as we
used a different methodological approach with open
questions and no concrete PM-example as stimulus (the
experts in [10] were asked explicitly about the implications
of their own development, the Rectumchip).
Apart from these methodological considerations, it is
particularly the neglect of potential discrimination resulting
from personalized therapeutic measures that is striking:
after all, disadvantages for certain patient subgroups are to
be feared as a consequence of secondary information
regarding the prognosis and efficacy of treatments gained
by diagnostic tests. This becomes clear by analyzing the
praxis of applying the agent Trastuzumab (Herceptin®)
for treatment of breast cancer. The drug, especially
when applied in combination with chemotherapy or as
an adjuvant (postoperative) treatment, significantly improves
the response rate and the progression-free as well as
overall survival rate in patients with an overexpression of
the HER2/neu receptor (HER2/neu positive) as compared
to HER2/neu negative patients [15-19]. For this reason, in
Germany in the year 2000, treatment with Trastuzumab
has been tied down to an HER2/neu positive test result
[11]. This practice, however, means to categorize breast can-
cer patients as either “good responders”, “non-responders”
or “difficult to treat“, which is at least a potential cause of
discrimination: such categorizations eventually result in
restricting access for the subpopulations labeled as
“non-responder” or “difficult to treat” to health care
interventions and health insurances or disadvantaging
them in other areas, for instance on the job market
[20-23]. As was the case for the respondents’ focus on
oncology, a possible reason for their neglect of these issues
probably lies in the specific composition of our sample:
respondents may had only such agents in mind that are
positively connoted (e.g. Imatinib) [24], while not bearing
in mind negatively connoted ones (e.g. Cetuximab) [25].
In summary, the results of our study show at least two
biases in the discourse about PM: first, the respondents’
almost exclusively focus on the field of oncology and
second, their neglect of certain ethical concerns. Needless
to say, these biases indicate a fundamental problem of the
ethical discourse on PM: ethical concerns in many cases
apparently do not adequately reflect PM’s current state of
Table 2 Stakeholders’ ethical concerns by fields of PM
Fields of PM
Research Clinical Use (Health Care)
Prevention Treatment
Ethical Concerns Individual Level Informed Consent for Biomarker Studies Impact on Individual Well-Being Higher Risks for Patients
Confidentiality & Data Protection Confidentiality & Data Protection
Right to Know/Right not to Know Right to Know/Right not to Know
Study Designs (Patient Relevant Outcomes) Increased Individual Responsibility for Health
Societal Level Allocation of Resources (Genetic) Discrimination Distribution
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of its future developments. This impression also is
supported by the fact that, although most respondents
assessed future developments of personalized prevention
rather pessimistically, they nevertheless located a multitude
of potential ethical issues in this context. On the other
hand, relatively few concerns were mentioned regarding
personalized therapeutic approaches even though their
future developments were assessed much more optimis-
tically. As regards future developments of PM the ethical
evaluation seems to follow the rule: the less likely its
application (i.e. a pessimistic assessment), the more
problematic a PM measure is assessed. The more likely
its application (i.e. an optimistic assessment), on the
other hand, the less problematic it is evaluated. As a
consequence, ethical discourse on PM runs the risk of
debating (currently) less relevant ethical concerns while
neglecting more relevant ones.
Conclusions
Against this background, our findings strongly suggest a
re-adjustment of the ethical debate on PM. A constructive
ethical monitoring must ensure to include only, never-
theless all of the actual and/or potential concerns that
are ethically relevant in order to allow balancing them
against the actual and potential ethically relevant benefits
of PM measures. This is the only way to ensure an
ethical monitoring of PM’s developments and clinical
usage, which carves out ethical issues while not, on
the other hand, retarding reasonable developments
and applications.
Yet, as has been noted above, PM is a rather heteroge-
neous field of development and application. Therefore,
ethically relevant concerns differ decisively with regard
to different PM measures. On this account, an overall
assessment of PM’s (potential) ethical issues is impossible.
Rather, an adequate evaluation strategy requires assessing
each personalized approach separately with regard to its
actual or potential concerns. Furthermore, it is necessary
to re-focus towards more likely fields of application.
Consequently, in order to determine ethically relevant
concerns of a certain PM intervention, its respectivecurrent state of research and clinical usage as well as its
expected future developments has to be analyzed and
evaluated. It generally holds: the less likely that a PM
measure be applied, the less relevant are the concerns
associated with it. The more likely that a PM measure be
applied, the more relevant are the concerns associated
with it. However, the (potential) impact of an ethical
concern on individual patients as well as the healthcare
system and the society is also important for evaluating its
relevance. With respect to this aspect it holds: the less
critical a concern associated with a PM measure, the less
relevant it is for evaluating the measure. The more critical
a concern, the more relevant it is. Needless to say, evaluating
a (potential) impact as highly critical may makes is necessary
to regard concerns as relevant that are associated with
PM measures whose application is unlikely. After all,
the quality of an ethical concern may overrule the results
of evaluating the current state of research and clinical
usage as well as the expected future developments of an
PM measure. Thus, the more critical an ethical concern
associated with an PM measure is, the less important is
the likelihood of the measures’ application for evaluating
the concerns’ relevance and vice versa. It is obvious,
however, that this criterion again increases the risk of
debating irrelevant ethical concerns, either if concerns
are evaluated as highly critical which are very unlikely
to occur, or if critical concerns are associated with PM
measures whose application is very unlikely. In order to
avoid such debates, both (potential) ethical concerns
and the application of a PM measure have to be plausible
to a certain degree in order to qualify a concern as
relevant [26]. If this is guaranteed, we claim that ethical
concerns should have priority in the ethical discourse
according to our criteria of relevance. As none of the
potential concerns seems to arise exclusively in the context
of PM, they can be approached by referring to standard
bioethics debates and applying accordant approaches.
Limitations
Like in all qualitative research, the empirical results of this
study are not representative, but rather dependent on the
particular sample underlying the analysis. Consequently,
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discourse on PM is inferred from the empirical results of a
qualitative study, it is to be understood as a hypothesis,
which has to be supported by further quantitative studies,
e.g. on the ethical concerns mentioned by a representative
sample of stakeholders in the German healthcare system.
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